CTIS2022-502067-38-00进行中（未招募）1 期
Effect of neoadjuvant Degarelix on MRI-guided transurethral ultrasound ablation in patients with intermediate-risk prostate cancer: A pilot study
Turku University Central Hospital0 个研究点目标入组 15 人开始时间: 2022年11月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Male age = 40 years, candidate for radical Pca treatment, Informed consent: The patient must speak Finnish, English, or Swedish and must be able to understand the meaning of the study. The patient must be willing and able to sign the appropriate Ethics Committee (EC) approved informed consent documents in the presence of the designated staff., Estimated life expectancy > 8 years, At least one MRI-visible and biopsy-concordant tumor defined as Prostate Imaging–Reporting and Data System v2 (PI-RADS v2.1) =3, Biopsy-confirmed, intermediate-risk localized Pca: Clinical or radiological stage = T2c, N0, M0, ISUP GG 2 or 3, Biopsy obtained = 6 weeks and = 12 months before treatment, PSA = 20 ng/ml, No prior definitive treatment of Pca, Eligible for MRI, Eligible for general anesthesia (American Society of Anesthesiologists Class III or less, Patients taking 5-alpha reductase inhibitors (5-ARIs) are eligible if use is discontinued 12 months before and throughout the study period
排除标准
- •Prior Pca treatment with chemotherapy or hormonal therapy, including chemical or surgical castration, antiandrogen therapy, or androgen synthesis inhibitors, Known allergy or contraindication to gadolinium or gastro-intestinal anti-spasmodic drug (e.g., glucagon, buscopan), Any other conditions that might compromise patient safety, based on the clinical judgment of the responsible urologist, Secondary malignancy unless disease-free survival is > 8 years, Relative or absolute contraindication to degarelix, Severe, active cardiovascular comorbidity including unstable angina pectoris, congestive heart failure, deep vein thrombosis, pulmonary embolism, or myocardial infarction within the last six months, Inability to undergo MRI due to claustrophobia or contraindications (cardiac pacemaker, intracranial clips, etc., Prostate calcifications obstructing the planned ultrasound beam path in the line of sight of the MRI visible tumo, Prostate cysts at the prostate capsule within the planned ultrasound beam path in the line of sight of the MRI visible tumo, Evidence of extraprostatic disease based on imaging (MRI, bone scintigraphy, single-photon emission tomography, computed tomography, prostate-specific membrane antigen-positron emission tomography [PSMA-PET]) or histopatholog, History of chronic inflammatory conditions (e.g., inflammatory bowel disease) affecting the rectum (also includes rectal fistula and anal/rectal stenosis), Hip replacement surgery or other metal in the pelvic area
研究者
相似试验
进行中（未招募）
1 期
Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate CancerProstate CancerLocalized Prostate CarcinomaCastration-Naive Prostate CancerIntermediate Risk Prostate CancerNCT05917860Turku University Hospital15
进行中（未招募）
不适用
Functional MRI after administration of Gd-based blood pool contrast agentsEUCTR2007-006724-35-SECMIV
已完成
4 期
'Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) as an outcome measure to evaluate the effectiveness of intra-articular hyaluronic acid for knee osteoarthritis'arthrosismultifactorial chronic joint disease10023213NL-OMON34935Erasmus MC, Universitair Medisch Centrum Rotterdam20
进行中（未招募）
不适用
'Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) as an outcome measure to evaluate the effectiveness of intra-articular hyaluronic acid for knee osteoarthritis’ - Efficacy of Hyaluron injections for knee OAOsteoarthritis of the kneeEUCTR2010-019019-39-NLErasmus MC
招募中
不适用
Efficacy of gadoxetic acid-enhanced MRI in assessing tumor regression after radiofrequency ablation for hepatocellular carcinoma - comparison with CThepatocellular carcinomaJPRN-UMIN000004571Tokai University School of Medicine Department of Gastroenterology50